scispace - formally typeset
B

Brian M. Wolpin

Researcher at Harvard University

Publications -  305
Citations -  21474

Brian M. Wolpin is an academic researcher from Harvard University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 67, co-authored 257 publications receiving 16470 citations. Previous affiliations of Brian M. Wolpin include Yale University & Brigham and Women's Hospital.

Papers
More filters
Journal ArticleDOI

Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology

TL;DR: The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection, as well as on management of locally advanced unresectable and metastatic disease.
Journal ArticleDOI

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

Hervé Tiriac, +73 more
- 31 May 2018 - 
TL;DR: A pancreatic cancer patient-derived organoid (PDO) library is generated that recapitulates the mutational spectrum and transcriptional subtypes of primary Pancreatic cancer and proposes that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.
Journal ArticleDOI

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Laufey T. Amundadottir, +77 more
- 01 Sep 2009 - 
TL;DR: In this paper, a two-stage genome-wide association study of pancreatic cancer, a cancer with one of the lowest survival rates worldwide, was conducted, where 558,542 SNPs were genotyped in 1,896 individuals and 1,939 controls drawn from 12 prospective cohorts plus one hospital-based case-control study.

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Laufey T. Amundadottir, +77 more
TL;DR: An association between a locus on 9q34 and pancreatic cancer marked by the SNP rs505922 is identified, consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk of pancreaticcancer than those with groups A or B.